Spero Therapeutics (SPRO) Stock Statistics & Valuation Metrics

Spero Therapeutics has a market cap or net worth of $120.99M. The enterprise value is $134.90M.

Spero Therapeutics has 56,275,227 shares outstanding. The number of shares has decreased by -2.65% in one year.

Spero Therapeutics’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -116.05%.

The current PE Ratio of Spero Therapeutics is 10.8. Spero Therapeutics’s PEG ratio is ―.

In the last 12 months, Spero Therapeutics had revenue of 27.40M and earned -68.57M in profits. Earnings per share was -1.27.

In the last 12 months, operating cash flow was -32.33M and capital expenditures 0.00, giving a free cash flow of -32.33M billion.

Spero Therapeutics pays an annual dividend of $0.015, resulting in a dividend yield of ―

Spero Therapeutics upcoming earnings date is Nov 17, 2025, TBA (Confirmed).

Spero Therapeutics as a current ratio of 2.19, with Debt / Equity ratio of 11.01%

In the past 12 months, Spero Therapeutics has paid 0.00 in taxes.

Spero Therapeutics EV to EBITDA ratio is -0.10, with an EV/FCF ratio of -0.30.

Spero Therapeutics has $31.19M in cash and marketable securities with $3.62M in debt, giving a net cash position of -$27.58M billion.

Gross margin is 66.92%, with operating margin of -267.78%, and net profit margin of -250.28%.

The average price target for Spero Therapeutics is $4.00, which is 11.43% higher than the current price. The consensus rating is Hold